Answers are grounded in this paper and cite their sources.
Case report reveals fatal interstitial lung disease following neoadjuvant nivolumab in lung cancer, suggesting important clinical implications.
INTRODUCTION: Neoadjuvant immunotherapy with nivolumab combined with chemotherapy has become a standard treatment for resectable non-small cell lung cancer (NSCLC), demonstrating improved survival outcomes. However, immune checkpoint inhibitors (ICIs) such as nivolumab are associated with immune-related adverse events, including interstitial lung disease (ILD). While ILD is a recognized complication in advanced NSCLC, its occurrence following neoadjuvant ICI therapy and subsequent surgical resection is rarely reported.
No takes yet. Share an insight, caveat, or question.
Osako et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: